Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer.

Hui-Ming LinKevin HuynhManish KohliWinston TanArun A AzadNicole YeungKate L MahonBlossom MakPeter D SutherlandAndrew ShepherdNatalie MellettMaria DocantoCorey GilesMargaret M CenteneraLisa M ButlerPeter J MeikleLisa G Horvath

Published in: Prostate cancer and prostatic diseases (2021)

Elevated circulating ceramide species are associated with poorer clinical outcomes across the natural history of PC. These clinically actionable lipid profiles could be therapeutically targeted in prospective clinical trials to potentially improve PC outcomes.

Keyphrases

prostate cancer
clinical trial
radical prostatectomy
small cell lung cancer
copy number
cancer therapy
type diabetes
randomized controlled trial
metabolic syndrome
skeletal muscle
dna methylation
open label
double blind